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High CD8 Cell Doses Correlate with Reduced Relapse Risk
and Improved Survival after Allogeneic Peripheral Blood
Stem-Cell Transplantation with Reduced-Intensity
Conditioning
Ran Reshef, Selina Luger, Alison Loren, Elizabeth O. Hexner,
Sunita D. Nasta, Noelle V. Frey, Edward A. Stadtmauer,
Jacqueline Smith, David L. Porter. Blood and Marrow
Transplantation Program, Abramson Cancer Center, Perelman
School of Medicine at the University of Pennsylvania,
Philadelphia, PA
Background: Disease relapse remains the most common
cause of death after allogeneic hematopoietic stem-cell
transplantation (SCT). Speciﬁcally, prevention of relapse in
transplants performed after reduced intensity conditioning
(RIC) relies on a donor derived graft-versus-tumor (GVT)
effect, which is primarily mediated by T-cells. We hypothe-
sized that a high graft T-cell dose enhances GVT and im-
proves outcomes. We therefore analyzed the impact of graft
composition on transplant outcomes in patients undergoing
allogeneic peripheral blood SCT with a uniform RIC regimen.
Methods: We studied 183 consecutive patients who under-
went a ﬁrst allogeneic SCT with peripheral blood stem-cells
and ﬂudarabine (120mg/m2) + busulfan (6.4mg/kg) condi-
tioning. Patients were allografted at the University of Penn-
sylvania between August 2006 and March 2013. Doses of
CD3, CD8, CD4 and CD34 cells in the graft were determined
by standard methods. Univariate analyses of outcomes were
performed using cumulative incidence and Cox regression
analyses. Multivariable models were constructed using the
backward elimination method, including variables with
p<0.1.
Results: The median follow-up was 20.2 mo. (range 0.4 e
78). Patients had a median age of 62 (range 21-76) and dis-
eases included AML (71), MDS (45), NHL (38), CLL (9), ALL (5)
and others (15). Mean cell doses were CD3: 2.2x108/kg (range
0.17-5.5), CD8: 0.38x108/kg (range 0.03 e 1.49), CD4:
0.96x108/kg (range 0.1 e 3.05) and CD34: 5.8x106/kg (range
1.2-21.4).
A univariate analysis of overall survival showed a trend
for improved survival in patients with high CD8 cell doses
(HR¼0.51, 95%CI [0.24,1.09], p¼0.08). The total nucleated cell
dose signiﬁcantly correlated with overall survival (HR¼0.95,
[0.90, 0.99], p¼0.04). In a multivariate model CD8 cell doses
signiﬁcantly correlated with improved survival (HR¼0.41,
[0.19, 0.91], p¼0.03).Figure 1. The impact of CD8 cell dose on RFSSimilar analyses of the relapse risk and relapse free sur-
vival revealed a signiﬁcant protective effect of high CD8 cell
doses (HR¼0.36, [0.15, 0.90], p¼0.03 and HR¼0.46, [0.23,
0.93], p¼0.03, respectively). Figure 1 illustrates the impact of
high (>0.7) and low CD8 cell doses on relapse-free survival.
Acute graft-versus-host disease (GVHD) did not correlate
with T-cell doses, but the risk for moderate-severe chronic
GVHD was higher in patients who received high CD8 cell
doses without reaching statistical signiﬁcance (HR¼3.35,
[0.93, 12.05], p¼0.06).
Conclusion: CD8 dose predicts clinical outcome in patients
undergoing peripheral blood RIC SCT. A higher CD8 cell dose
is a primary predictor of a lower relapse rate and improved
relapse-free and overall survival, while there is a possible
increase in chronic GVHD. Targeting high CD8 cell doses
should be considered in prospective trials of reduced in-
tensity conditioned SCT.
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Patients given allogeneic hematopoietic transplants (HSCT)
may develop subsequent malignant neoplasms (SMN).
Several variables have been identiﬁed but there are no data
about the incidence of this complication in individuals given
HSCT using reduced-intensity conditioning (RIC) methods.
The objective of this study is to deﬁne the incidence of SMN
in patients given HSCT using a RIC preparative regimen
conducted on an outpatient basis. Patients given HSCT in two
institutions between October 1998 and 2012 were analyzed.
Overall survival was analyzed with the Kaplan-Meier pro-
cedure. Patients alive at the closure of the study or those lost
to follow upwere censored. To appraise the SMNappearance,
those patients dead were also regarded as censored at that
moment, as well as those lost to follow up and those alive at
the closing of the study. 95% conﬁdence intervals for the
survival or failure estimate were calculated with the Green-
wood’s method. All the survival analyses were processed
with the StataCorp 2005. Stata Statistical Software: Release 9.
College Station, TX: StataCorp LP. A total of 416 allografted
patients with a Karnofsky performance index of 100% were
included in the study. All patients received PBSC allografts.
Engraftment occurred in 350 patients (84%). The condition-
ing regimen was delivered as an outpatient procedure in all
individuals. No patient was given radiotherapy nor antithy-
mocyte globulin during the conditioning. Three hundred and
sixty ﬁve patients (88%) were never admitted to the hospital,
whereas 12% were admitted because of grade III-IV aGVHD,
fever or mucositis. Median survival time was 15.7 months.
Survival at 6 months (95% CI): 66.4% (61.5- 70.8%), at
12 months: 53.3% (48.1 -58.1%), at 60 months: 30.6%
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the group of 416 allografted patients, the cumulative prob-
ability of SMN being 6.8 at 10 years. Since the number of
expected cases in the general population is 0.62, the ratio of
observed to expected cases is 3.2 (p < 0.001). This ﬁgure
means that the risk of developing a malignant neoplasm in
allografted individuals using our method is 3.2 times higher
than that in the general population. There were three non-
Hodgkin’s lymphomas (NHL), two M2 acute myelogenous
leukemias (AML), one hairy cell leukemia, one tongue
epidermoid carcinoma and one breast carcinoma. In
conclusion, we have found a low incidence of SMN in this
group of Mexican patients allografted with the Mexican
reduced-intensity conditioning method. Possible explana-
tions for this difference are discussed, focusing on the RIC
preparative regimen.387
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Objective: To demonstrate the efﬁcacy and safety of a
reduced intensity conditioning (RIC) regimen comprising
Fludarabine and intravenous Busulfan (FB2) in patients un-
dergoing allogeneic peripheral blood stem cell trans-
plantation (PBSCT) for hematological disorders.
Patients and Methods: We conducted a retrospective anal-
ysis of 42 patients who underwent RIC prior to PBSCT at our
institution between the years 2009 and 2012 inclusive. FB2
consisted of Fludarabine 30 mg/m2/day infused over 30 mi-
nutes for 5 days on days -6 through -2 and Busulfan 3.2 mg/
kg/day on days -3 and -2 (infusion rate 80 mg/kg/hour). All
patients received Thymoglobulin at a total dose of 4.5 mg/kg
or 6 mg/kg administered in divided doses on days -2, -1 and
0. Post-transplantation graft versus host disease (GVHD)
prophylaxis consisted of tacrolimus and mycophenolate
mofetil. Diagnoses included Acute Myeloid Leukemia (n¼3),
Acute Lymphoblastic Leukemia (n¼2), Myelodysplastic Syn-
drome (n¼10), Severe Aplastic Anemia (n¼5), Chronic Lym-
phocytic Lymphoma (n¼8), Non-Hodgkin’s Lymphoma
(n¼8), Hodgkin Lymphoma (n¼4) and Myeloproliferative
Disorder (n¼2). The median age of the recipients was 56
years with 18 patients (44%) aged> 60 years. Only 9 patients
(21%) were in complete remission (CR) at the time of HSCT
and 19 (45%) were considered to have high-risk disease by
CIBMTR criteria. The co-morbidity index was 3 or more in 19
recipients (45%).
Results: At a median follow up of 15 months, overall survival
(OS) for the entire cohort was 62%. OS for patients under-
going PBSCT in CR versus not in CR was 89% and 55%
respectively. OS was similar in recipients undergoing PBSCT
from matched unrelated (n¼29) or matched related (n¼13)
donors. Median engraftment time for neutrophils (ANC>500) and platelets (>20K) was 18 and 17 days, respectively.
Acute GVHD grade 2 developed in 15 (36%) of recipients,
grade 3 in 2 (5%) and grade 4 in 2 (5%). The cumulative
incidence of relapse was 37% (n¼13). There were no graft
failures and treatment relatedmortality (TRM)was 2% (n¼1).
At one year following PBSCT, 10 patients (24%) had extensive
chronic GVHD and 19 patients (45%) required continuation of
immunosuppressants. All patients with SAA (n¼5) are alive,
engrafted and did not develop grade 3 or 4 acute GVHD.
Conclusion: Our preliminary data demonstrates low toxicity
and favorable outcome in older patients with elevated co-
morbidity score and high-risk disease using the FB2 regimen.
The efﬁcacy, tolerability and excellent outcome of FB2 war-
rants further study in recipients with SAA.388
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Introduction: Graft Versus Host Disease (GVHD) and
immunosuppression in allogeneic hematopoietic stem cell
transplant (alloHSCT) patients can contribute to cytomega-
lovirus (CMV) disease. CMV disease of the gut is associated
with intestinal necrosis and ulceration and can lead to
debilitating diarrhea. Diagnostic evaluation includes assess-
ment for CMV viremia and intestinal biopsy to conﬁrm
diagnosis. Adequate research supporting intestinal biopsy in
serum negative patients does not exist. In an effort to
potentially minimize use of invasive endoscopic procedures
to rule out CMV as a cause for diarrhea, we evaluated the
diagnostic yield of intestinal biopsies in the work-up of
allograft recipients presenting with diarrhea.
Methods: This retrospective study evaluated a total of 485
patients that underwent alloHSCT after 2006 and were
admitted to the inpatient BMT service between January 1st,
2008 and April 30th, 2013. A subset of patients was identiﬁed
that completed esophagogastroduodenoscopy (EGD) or co-
lonoscopy for work-up of diarrhea. Comparisons were made
between serum CMV PCR (108 bp primer directed at CMV
Immediate Early antigen product) and gastrointestinal bi-
opsy (with morphologic evaluation for cytopathic effect and
immunohistochemistry for immediate early non-structural
antigen). Pathologic evaluation conﬁrmed gut-associated
CMV disease.
Results: CMV viremia was evident the day of intestinal bi-
opsy 25% (99 total biopsies) of the time. Nine biopsies (9%) in
7 different patients were positive for CMV and conﬁrmed
CMV gut disease. Of these, 6 patients had corresponding
CMV viremia. One patient (cord blood recipient) was diag-
nosed with CMV gut disease by biopsy alone. Signiﬁcant
association (p¼0.003) and agreement (p¼0.006) between
CMV viremia and CMV gut disease were observed in this
cohort, although we do note discordances of interest. No
apparent association between lymphocyte count and the
presence of CMV intestinal diseasewas observed (p¼0.23). In
